Table 1.
Effects of siRNA/inhibitor treatments on sensory epithelia proliferation
| siRNA/inhibitor treatment | Inhibit proliferation | Average fold knockdown | Regeneration pathway/category |
|---|---|---|---|
| CEBPG | Yes | −3.92 | AP-1 pathway |
| JNK inhibitor | Yes | ||
| JUND | Yes | * | |
| BTAF1 | Yes | −1.57 | AP-1 siRNA commonalities |
| LRP5 | Yes | −5.71 | |
| RARA | Yes | −1.41 | |
| PAX2 | Yes | −1.61 | Pax pathway |
| PAX3 | No | −1.61 | |
| PAX5 | Yes | * | |
| PAX7 | No | −1.72 | |
| MYT1L | No | * | AP-1/Pax siRNA commonalities |
| WNT4 | Yes | −2.27 | |
| CUTL1 | Yes | −1.86 | Cell cycle |
| p27KIP | No | −2.93 | |
| ID1 | No | −1.48 | |
| CBX3 | No | −4.15 | Polycomb complex |
| CBX4 | No | −1.09 | |
| EZH2 | No | −1.87 | |
| IGF inhibitor | No | Pathway inhibitors | |
| MAPK inhibitor | Yes | ||
| SHH inhibitor | No | ||
| HRY | No | −1.30 | Notch signaling |
| BCL11A | No | −1.35 | Common to all tissues/damage |
| TRIP15 | No | −1.12 | |
| CTNNB1 | No | −2.39 | Common to cochlea and utricle |
| TIME | No | −1.16 | Early regeneration |
| PPARGC1 | No | −1.42 | Neomycin specific |
Proliferation phenotypes were quantified for each siRNA knockdown. Inhibition was determined as a significantly lower proliferation index than a GFP siRNA control (p < 0.05). Knockdowns of siRNA targets were confirmed by microarray analysis or (*) endpoint semiquantitative PCR.